Facioscapulohumeral muscular dystrophy (FSHD) illustrates why a genetic diagnosis sometimes requires analysis beyond a list of sequence variants. Clinical recognition, a repetitive chromosome region and its regulatory context all matter. For clinicians, the practical task is to establish whether the molecular finding explains the presentation, then distinguish that conclusion from predictions about future disability.
Recognize the pattern without requiring every feature
FSHD commonly affects facial muscles, shoulder blade stabilizers and upper arms. Scapular winging and difficulty raising the arms can be prominent. Foot drop, abdominal weakness and later hip involvement can also occur. Facial weakness may affect smiling or complete eye closure. Onset ranges from childhood to late adulthood, and severity varies substantially. FSHD1 and FSHD2 have similar clinical manifestations despite different genetic causes. MedlinePlus Genetics describes the clinical spectrum.
Document which muscles are weak, asymmetry, onset and functional consequences rather than relying on the diagnostic label alone. A family history should include subtle limitations as well as formally diagnosed muscular dystrophy. An apparently unaffected relative and an unexamined relative provide different information.
Understand the molecular question
Both forms involve inappropriate activity of DUX4, a gene normally silenced in most adult tissues. DUX4 lies within the D4Z4 repeat region near the end of chromosome 4. In FSHD1, the repeat array is contracted. Disease also requires a permissive chromosome background that supports production of the DUX4 message. A repeat count therefore needs its chromosome context. MedlinePlus explains D4Z4 and permissive chromosome 4 backgrounds.
FSHD1 and the borderline range
The 2024 international diagnostic consensus describes FSHD1-associated arrays of 1–10 repeat units, with particular uncertainty around 8–10 units. This range overlaps findings in unaffected people. Threshold evidence largely reflects European ancestry populations, limiting simple generalization. Repeat size must be interpreted alongside examination, family evidence and other molecular findings. The diagnostic consensus discusses this overlap.
FSHD2 requires a broader assessment
FSHD2 involves reduced D4Z4 methylation and a permissive chromosome background, often with a pathogenic variant in SMCHD1, which helps regulate chromatin. Testing can therefore require repeat characterization, methylation analysis and gene analysis. A negative contraction result alone does not answer every FSHD question. The consensus sets out FSHD2 testing requirements.
Read the report as an explanation of what was measured
Useful report review asks whether the laboratory established:
- The repeat size and relevant chromosome background.
- Whether complex repeat structures or mosaicism could affect interpretation.
- Whether further methylation or gene testing is indicated.
Specialized methods include Southern blotting, molecular combing and optical genome mapping. Their capabilities differ; the consensus also recommends assessing mosaicism in sporadic cases. Clarification with the laboratory is valuable when the report and phenotype do not align. See the method-specific recommendations.
Separate diagnosis, prognosis and established care
Smaller repeat arrays are associated with greater severity at a group level, but cannot reliably predict an individual’s course. Clinical follow-up remains necessary. The 2015 AAN/AANEM guideline recommends baseline pulmonary function testing, with further monitoring according to findings and risk factors. It also addresses pain, childhood hearing assessment and retinal evaluation in people with large contractions. The guideline explains these recommendations and their evidence limits.
Rehabilitation, functional support and selected surgical assessment address existing needs. Molecular confirmation may also support trial eligibility, but it does not establish treatment benefit. Research outcomes must demonstrate meaningful functional improvement and acceptable safety; a biological rationale alone cannot do so. The 2015 care guideline is a dated evidence synthesis, not a current inventory of investigational therapies. Its treatment assessment should be distinguished from the 2024 diagnostic consensus.